Anorectic drugs and pulmonary hypertension from the bedside to the bench
- PMID: 11307870
- DOI: 10.1097/00000441-200104000-00009
Anorectic drugs and pulmonary hypertension from the bedside to the bench
Abstract
Anorectic drugs have been used for more than 30 years as an aid in weight reduction for obese persons. The use of aminorex, an amphetamine analog that increases norepinephrine levels in the central nervous system, led to an epidemic of primary pulmonary hypertension (PPH) in Europe in the late 1960s and early 1970s. The use of fenfluramine and later dexfenfluramine [drugs that inhibit 5-hydroxytryptamine (5-HT) release and reuptake and increases 5-HT and thus 5-HT secretion in the brain] was associated with a second epidemic of PPH. All of these drugs have been voluntarily withdrawn from the market. The pathogenesis of PPH in patients treated with these agents is uncertain, but recent evidence suggests that potassium channel abnormalities and vasoactive and proliferative properties of 5-HT may play a role. There is increasing experimental evidence suggesting that aminorex, fenfluramine and dexfenfluramine inhibit 4-aminopyridine-sensitive currents in potassium channels resulting in vasoconstriction in pulmonary resistance vessels and perhaps smooth muscle cell proliferation. 5-HT causes pulmonary artery vasoconstriction and smooth muscle cell proliferation. Its levels are known to be high in those with fenfluramine-induced PPH. However, a firm cause-and-effect relationship has not yet been established. One potentially beneficial effect of the epidemics of anorectic-related PPH is that it may have provided important insights into the causes of PPH unrelated to anorectic agents.
Similar articles
-
Aminorex, dexfenfluramine, and primary pulmonary hypertension.J Clin Epidemiol. 1998 Apr;51(4):361-4. doi: 10.1016/s0895-4356(97)00289-8. J Clin Epidemiol. 1998. PMID: 9539893
-
Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction.Circulation. 1996 Nov 1;94(9):2216-20. doi: 10.1161/01.cir.94.9.2216. Circulation. 1996. PMID: 8901674
-
Appetite suppressants and cardiac valvulopathy. Current clinical perspectives.Adv Nurse Pract. 1999 Oct;7(10):36-40. Adv Nurse Pract. 1999. PMID: 10808770 Review.
-
Anorexigen-related cardiopulmonary toxicity.Rev Cardiovasc Med. 2000 Fall;1(2):80-9, 102. Rev Cardiovasc Med. 2000. PMID: 12457145 Review.
-
A role for potassium channels in smooth muscle cells and platelets in the etiology of primary pulmonary hypertension.Chest. 1998 Sep;114(3 Suppl):200S-204S. doi: 10.1378/chest.114.3_supplement.200s. Chest. 1998. PMID: 9741569 Review.
Cited by
-
Safety of drug therapies used for weight loss and treatment of obesity.Drug Saf. 2006;29(4):277-302. doi: 10.2165/00002018-200629040-00001. Drug Saf. 2006. PMID: 16569079 Review.
-
Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions.AAPS J. 2007 Jan 5;9(1):E1-10. doi: 10.1208/aapsj0901001. AAPS J. 2007. PMID: 17408232 Free PMC article. Review.
-
Challenges in pulmonary risk assessment and perioperative management in bariatric surgery patients.Obes Surg. 2008 Jan;18(1):134-8. doi: 10.1007/s11695-007-9282-0. Epub 2007 Nov 16. Obes Surg. 2008. PMID: 18008109 Review.
-
Obesity and pulmonary hypertension: a review of pathophysiologic mechanisms.J Obes. 2012;2012:505274. doi: 10.1155/2012/505274. Epub 2012 Sep 3. J Obes. 2012. PMID: 22988490 Free PMC article.
-
Centrally Acting Agents for Obesity: Past, Present, and Future.Drugs. 2018 Jul;78(11):1113-1132. doi: 10.1007/s40265-018-0946-y. Drugs. 2018. PMID: 30014268 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical